In 2023, the Centers for Disease Control and Prevention reported that more than 40% of American adults live with obesity
PSG conducted a comprehensive survey of over 200 healthcare payers, including health plans and employers, to better understand their perspectives on the use of GLP-1s for treatment of obesity
(1996) published early clinical research findings in Life Sciences demonstrating MT-2's melanogenic effects in human subjects, establishing the peptide's potency as a melanocortin agonist
Lower-Risk Profile Compared to Direct GH Because sermorelin works through the body's own feedback system, the risk of pushing GH or IGF-1 too high is built-in lower than with direct recombinant GH injections
Josefson JL, Catalano PM, Lowe WL, Scholtens DM, Kuang A, Dyer AR, et al
Instead, the body draws from both fat and muscle